Clinical Trial Detail

NCT ID NCT03539822
Title Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Anwaar Saeed
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

hepatocellular carcinoma

colorectal adenocarcinoma

Therapies

Cabozantinib + Durvalumab

Age Groups: senior adult

No variant requirements are available.